

## **Dr Carl Dolman**

## **Publications**

Dolman C, Thorpe SJ and Thorpe R. Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content. *Biologicals* 2001; 29: 75-79.

Thorpe SJ, Fox BJ, Dolman CD, Lawrence J and Thorpe R. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity. *Vox Sang* 2003; 85: 80-84.

Thorpe SJ, Fox BJ, Dolman CD and Thorpe R. Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method. *Biologicals* 2005; 33: 111-116.

Thorpe SJ, Fox B, Heath A, Dolman C, Virata ML, Yu M-Y W and Thorpe R. International collaborative study to evaluate a candidate reference preparation to define an appropriate specified limit of anti-D in IVIG products. *Vox Sang* 2005; 88: 278-287.

Further publications can be found here: <a href="http://www.researcherid.com/rid/E-2485-2013">http://www.researcherid.com/rid/E-2485-2013</a>

